Our pipeline consists of four clinically enabled compounds, carefully selected from over 140 molecules considered by the Flexion team.
| Product | Initial Indication | Stage | ||||
|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
| FX002: Autoimmune Disease | x | x | |||
| FX003: Ulcerative Colitis | x | x | |||
| FX004: Tinnitus | x | x | x | ||
| FX005: Intra-articular Treatment of Osteoarthritis | x | ||||
Each compound has target validation, a strong safety profile, facilitated regulatory path, and the potential to address a large unmet medical need.
They have been chosen for progression not just to clinically meaningful proof of concept, but potentially into Ph 3 and commercialization. The Flexion pipeline could result in first-in-class and best-in-class drugs, providing important new options for physicians and patients.
Flexion continues to search for new opportunities to expand our specialty-care portfolio of anti-inflammatory therapeutics.